CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
B-type Natriuretic Peptide (BNP) +1 moredrug
Likely dose
B-type Natriuretic Peptide (BNP) 10 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00252187
NCT00252187Phase 2Completed
CompareCT.gov

Cardiac Hormone Replacement With BNP in Heart Failure: A Novel Therapeutic Strategy

Horng Chen·interventional·Posted Nov 11, 2005·Updated Dec 20, 2012

In Brief

A Phase 2 clinical trial evaluating B-type Natriuretic Peptide (BNP) and Placebo for Congestive Heart Failure and Cardiomyopathy. Completed, enrolled 45 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the effects of subcutaneous injection of Human BNP (nesiritide), a hormone produced by the heart, on the pumping ability of the heart, kidney function, and hormonal function in persons with heart failure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCongestive Heart Failure, Cardiomyopathy
CountriesUnited States
CollaboratorsAmerican Heart Association, Scios, Inc., National Heart, Lung, and Blood Institute (NHLBI), National Center for Research Resources (NCRR)

Timeline

Phase 2CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 11, 2005
Enrollment StartJan 1, 2000
Primary CompletionJul 1, 2008
Study CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 20.6 years ago

Interventions

B-type Natriuretic Peptide (BNP)drug

BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.

Placeboother

Placebo self-administered subcutaneously twice daily for 8 weeks.